News & Updates

Nightly use of 0.05% atropine eye drops among children appears to lead to a significantly lower incidence of near-sightedness, as shown in the results of the LAMP2 study from Hong Kong.

In a phase I/II study, the novel T-cell-engaging bispecific antibody glofitamab bares its potential for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

New drug applications approved by US FDA as of 01-15 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Mandatory training of healthcare professionals (HCPs) for the safe handling of cytotoxic drugs (CDs) conducted by a qualified oncology-pharmacist results in a decrease in the hazardous effects of CDs, reports a study.

Among Chinese patients with acute ischaemic stroke, intravenous (IV) tenecteplase is noninferior to the standard-of-care alteplase in achieving an excellent functional outcome, with a similar safety profile, when given within 4.5 hours of symptom onset, according to the TRACE-2* trial presented at ISC 2023.

A higher dose does not provide added benefits than a standard dose when it comes to vitamin D supplementation for bone mineral accretion in infants born with vitamin D insufficiency, as reported in a recent study.